Scotiabank raised the firm’s price target on BridgeBio (BBIO) to $45 from $44 and keeps an Outperform rating on the shares. The firm continues to like the setup for the company, with upcoming Prescription Drug User Fee Act for acoramidis on the horizon, which will give the company its first commercial product, the analyst tells investors. While many investors may have discounted acoramidis’ commercial potential in transthyretin amyloid cardiomyopathy due to competitive pressure from Alnylam’s (ALNY) vutrisiran, the firm believes the market is large enough to support commercial success for both drugs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BBIO:
- BridgeBio Pharma Reports Quarterly Loss Amid Restructuring
- BridgeBio reports Q3 EPS (86c), consensus (98c)
- BridgeBio announces publication on impact of biomedical innovation
- BBIO Upcoming Earnings Report: What to Expect?
- BridgeBio shares preliminary data from CANaspire Phase 1/2 trial of BBP-812
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
